Dr. Josep Tabernero, MD, PhD
Claim this profileVall d'Hebron
Studies Solid Tumors
Studies Stomach Cancer
5 reported clinical trials
7 drugs studied
Area of expertise
1Solid Tumors
Stage IV
Stage III
EGFR positive
2Stomach Cancer
metastatic
advanced
advanced inoperable
Clinical Trials Josep Tabernero, MD, PhD is currently running
More about Josep Tabernero, MD, PhD
Clinical Trial Related3 years of experience running clinical trials · Led 5 trials as a Principal Investigator · 1 Active Clinical TrialTreatments Josep Tabernero, MD, PhD has experience with
- SOT102
- MCLA-158
- Capecitabine
- CAPOX
- FOLFIRI
- RBN-2397
Breakdown of trials Josep Tabernero, MD, PhD has run
Solid Tumors
Colorectal Cancer
Uterine Tumors
Pancreatic Cancer
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Josep Tabernero, MD, PhD specialize in?
Josep Tabernero, MD, PhD focuses on Solid Tumors and Stomach Cancer. In particular, much of their work with Solid Tumors has involved Stage IV patients, or patients who are Stage III.
Is Josep Tabernero, MD, PhD currently recruiting for clinical trials?
Yes, Josep Tabernero, MD, PhD is currently recruiting for 1 clinical trial in the USA. If you're interested in participating, you should apply.
Are there any treatments that Josep Tabernero, MD, PhD has studied deeply?
Yes, Josep Tabernero, MD, PhD has studied treatments such as SOT102, MCLA-158, Capecitabine.
What is the best way to schedule an appointment with Josep Tabernero, MD, PhD?
Apply for one of the trials that Josep Tabernero, MD, PhD is conducting.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.